Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial

The Journal of Clinical Psychiatry
Hitoshi TakahashiHisashi Higuchi

Abstract

The efficacy and safety of switching to olanzapine were investigated in patients with first-episode schizophrenia who failed to attain an adequate clinical response to an initial therapeutic trial of risperidone (2-6 mg/day for 12 weeks). A total of 58 first-episode patients with DSM-IV schizophrenia who had residual symptoms following treatment with risperidone were enrolled in an open-label, 12-week study of olanzapine. Dosing was determined by clinical judgment. The main efficacy measure was the Brief Psychiatric Rating Scale (BPRS). Patients with a 20% or greater decrease in BPRS total score plus a final Clinical Global Impressions-Severity of Illness scale score of <or= 3 (mildly ill) were considered responders. The study was conducted from April 2001 to March 2005. Fifty-one patients completed the study, and 7 discontinued due to side effects and medication noncompliance. The mean dosage of olanzapine was 15.3 (SD 4.2) mg/day at study endpoint. Total BPRS scores significantly decreased (12.3%) during olanzapine treatment (p < .001). In addition, BPRS subscales of anxiety/depression and excitement significantly decreased (19.1% and 29.5%, respectively; p < .001). The responder rate was 29.3% (17/58). BPRS positive symptom ...Continue Reading

Citations

Sep 22, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ion-George AnghelescuMark E Schmidt
May 28, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ofer AgidGary Remington
Nov 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bruce J KinonJohn M Kane
May 29, 2009·Cost Effectiveness and Resource Allocation : C/E·Douglas E FariesHaya Ascher-Svanum
Apr 10, 2014·Evidence-based Mental Health·Markus Dold, Stefan Leucht
Apr 10, 2008·Current Medical Research and Opinion·Douglas E FariesBruce J Kinon
May 23, 2014·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Kotaro Hatta, Hiroto Ito
Jul 30, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Young Sup WooWon-Myong Bahk
Nov 20, 2014·Human Psychopharmacology·Yoshinori WatanabeTenpei Ohtsubo
Jun 4, 2015·Psychiatry and Clinical Neurosciences·Kotaro Hatta
Oct 17, 2018·NPJ Schizophrenia·Richard NewtonBenedicto Crespo-Facorro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Progress in Neuro-psychopharmacology & Biological Psychiatry
Hitoshi TakahashiHisashi Higuchi
The American Journal of Psychiatry
Susan EssockJeffrey A Lieberman
The New England Journal of Medicine
Jeffrey A LiebermanClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
© 2021 Meta ULC. All rights reserved